TUMOR INDUCED ANTIGEN SPECIFIC T CELL TOLERANCE

描述：诱导一个良好建立的回归的能力 通过“治疗性疫苗接种”的肿瘤负荷目前是有限的。 一 对此的解释是，通常防止不当行为的机制 对正常组织表达的“自身”抗原的攻击可使 对肿瘤表达的抗原作出反应的能力。 一个关键的问题， 肿瘤免疫学是指抗原是否通过进行性扩张 肿瘤细胞群导致T细胞耐受，如果是这样， 状态是可逆的。 利用对模型特异性的TCR转基因小鼠 在B细胞淋巴瘤上表达的肿瘤抗原，研究者获得了 支持存在肿瘤诱导的抗原特异性的证据 随着肿瘤进展而产生的耐受性。 的总体目标 该项目旨在进一步描述这种状态，重点关注 它的诱导机制，它发生的环境，以及 在主动免疫治疗的背景下探索其可逆性。

DESCRIPTION: The ability to induce the regression of a well established tumor burden via "therapeutic vaccination" is currently limited. One explanation for this is that mechanisms that normally prevent inappropriate attack against "self" antigens expressed by normal tissues may blunt the ability to respond to antigens expressed by tumors. A critical question in tumor immunology is whether antigen presented by progressively expanding tumor cell populations results in T cell tolerance, and, if so, if this state is reversible. Utilizing TCR transgenic mice specific for a model tumor antigen expressed on a B cell lymphoma, the investigator has obtained evidence supporting the existence of tumor-induced antigen specific tolerance that develops with tumor progression. The overall objective of this project is to further characterize this state, focusing on the mechanism of its induction, the settings in which it occurs, and an exploration of its reversibility in the context of active immunotherapy.